Defining the Standard of Care for Early Breast Cancer Treatment
June 4th 2024Heather Moore, BCOP, CPP, PharmD, discusses the importance of treatment for early breast cancer, highlighting the use of chemotherapy followed by endocrine therapy. She notes that CDK4/6 inhibitors are being added for higher-risk patients, and oral selective estrogen receptor degraders may also be used in advanced cases.
Academic and Community Practice Collaboration in mBC Treatment
June 4th 2024Frank Scimeca, PharmD, MBA, BCOP, discusses the crucial collaborative effort between academic and community practices in managing and monitoring patients receiving CDK4/6 inhibitors, emphasizing the importance of communication and coordination to ensure optimal patient care.
Empowering RSV Patients: Essential Vaccine Education Resources
June 4th 2024Medical professionals discuss the ongoing requirements in RSV treatment and vaccination, stressing the importance of at-risk populations maintaining hand hygiene, staying home when sick, and avoiding large crowds during peak seasons to minimize transmission, while also exploring the use of combination tests, panel testing, and rapid testing for RSV diagnosis.
Unmet Needs in Prevention and Management of RSV
June 4th 2024Rodney E. Rohde, PhD, SM, SV, MB (ASCP), FACSc, guides a conversation on patient education materials, recommending resources from the American Pharmacists Association, the Centers for Disease Control and Prevention, and the Advisory Committee on Immunization Practices, which provide tools to inform the public about vaccine-preventable diseases.
Sustained MRD-Negativity With Sc Daratumumab in Newly Diagnosed Multiple Myeloma
June 4th 2024Data from the PERSEUS trial supports use of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone followed by daratumumab and lenalidomide maintenance as a new standard of care for patients with newly diagnosed multiple myeloma.
Enhanced Front Line Therapy for NDMM: Promising Results from the MajesTEC-7 Trial
June 4th 2024Results from the initial safety run-in of MajesTEC-7 indicate that the combination of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma (NDMM) shows a manageable safety profile with early signs of efficacy.
Public Health Matters Video: Suicide Prevention and Reducing Mental Health Stigma
May 30th 2024Tune into this special episode of “Public Health Matters” to hear Emma White, the founder and president of the nonprofit organization Life Is Worth It, discuss her mental health journey and how she used it to educate adolescents, teenagers, and young adults on mental wellness.
Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting
May 29th 2024Ke Ning, MD, describes similarities and differences when implementing bispecific antibodies and CAR T-cell therapy for patients with relapsed or remitting multiple myeloma in the community oncology setting.
Role of Pharmacists in Operationalizing Bispecific Antibodies
May 29th 2024Medical professionals highlight the essential support provided by pharmacists in addressing operational challenges related to bispecific antibodies. Pharmacists can play an important role in the development of policies and procedures, monitoring and management of toxicities, and delivery of educational resources.
Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast Cancer
May 28th 2024Heather Moore, BCOP, CPP, PharmD, discusses switching from CDK4/6 inhibitors to later lines of therapy, typically due to toxicities, to alleviate symptoms. She emphasizes the goal of finding a new therapy rather than abandoning treatment altogether, and notes that targeted therapy may be necessary in cases of disease progression.
Navigating Financial Barriers: Cost-Saving Strategies and Patient Assistance Programs
May 28th 2024Frank Scimeca, PharmD, MBA, BCOP, discusses strategies for implementing cost-saving measures and utilizing patient assistance programs to help patients access therapy, while emphasizing the importance of mitigating financial toxicities for patients.
Team Approach to Meeting REMS Program Requirements
May 22nd 2024Sarah Rockwell, PharmD, BCOP, explores how community oncology practices can understand and meet the requirements of risk evaluation and mitigation strategy programs, and stresses the importance of developing and implementing standard operating procedures.